Chromane Derivatives as mGluR2 Negative Allosteric Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel non-competitive metabotropic glutamate receptor 2 (mGluR2) modulators, particularly negative allosteric modulators, to effectively treat Alzheimer's disease, cognitive impairment, schizophrenia, pain disorders, and sleep disorders, as existing compounds are not sufficient in modulating glutamate signaling effectively.
Innovation Solution
Development of novel substituted chromane, isochromane, and dihydroisobenzofuran derivatives that act as non-competitive negative allosteric modulators of the mGluR2 receptor, potentially improving cognitive function and alleviating symptoms of associated disorders by modulating glutamate release and signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing mGluR2 modulators are used, then some cognitive effects may be achieved, but they are not sufficient in modulating glutamate signaling effectively and lack functional selectivity
Solution Approach 1:
The patent employs negative allosteric modulators as intermediary compounds that bind to allosteric sites on the mGluR2 receptor rather than the orthosteric site. This intermediary binding mechanism allows modulation of glutamate signaling with functional selectivity, achieving reliable cognitive effects while avoiding the limitations of direct orthosteric antagonists. The allosteric modulators act as mediators between the drug molecule and the receptor's primary binding site.
2Reliability
If orthosteric binding site is targeted, then direct receptor antagonism is achieved, but functional selectivity is lost due to high conservation across all mGluR receptors
Solution Approach 1:
The patent applies local quality by targeting the allosteric site rather than the highly conserved orthosteric binding site. The allosteric site exhibits greater variability across different mGluR subtypes, allowing the designed compounds to achieve functional selectivity. This local targeting approach maintains reliable receptor antagonism while enabling differentiation between mGluR2 and other mGluR subtypes through selective allosteric binding.
3Productivity
If mGluR2 inhibition is implemented, then cognitive performance may improve, but existing compounds lack sufficient potency and efficacy
Solution Approach 1:
The patent utilizes parameter changes by systematically modifying chemical structures of allosteric modulators to optimize binding affinity and functional potency. The disclosed compounds represent optimized parameters including molecular weight, hydrophobicity, and specific functional group arrangements that enhance mGluR2 inhibition potency. These parameter optimizations enable reliable cognitive performance improvement with higher potency compared to existing compounds.
Data Source
AI summary
The present invention provides certain substituted chromane, isochromane, and dihydroisobenzofuran compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is a moiety selected from (II), (III), (IV), and (V), and ring B, n, R1, R2, R2A, R3, and R3A are as defined herein. The compounds of the invention are useful as mGluR2 inhibitors, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a patient for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, mild congnitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.